Stroke

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 2, 2024.

The associate professor of neurology at Vanderbilt University Medical Center discussed exploring promising opportunities in other phases outside of the acute phase of ischemic stroke. [WATCH TIME: 3 minutes]

For patients on apixaban, the risk of stroke or systemic embolism was lowered by 37% and the risk of disability or fatal stroke was lessened by 49%.

The chief executive officer of Aruna Bio discussed the reasons for the failure of neuroprotective agents in ischemic stroke trials and why AB126 has potential to restore neurodegeneration in such affected patients. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders.

Neurology News Network for the week ending January 27, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 26, 2024.

The chief executive officer of Aruna Bio discussed the mechanism of action behind AB126 and how its anti-inflammatory and neuroprotective properties may be effective in treating acute ischemic stroke. [WATCH TIME: 4 minutes]

Although there were no significant differences in the primary end secondary end points, patients with mRS scores of 0 to 2 at day 90 seemed to show better outcomes in the cell therapy group, particularly for those with ischemic core volumes of 50 mL or greater.

The chief executive officer of Aruna Bio provided context on a newly accepted phase 1/2 trial assessing the company’s neural-derived exosome agent AB126 in patients with acute ischemic stroke.

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital discussed the importance of early intervention, sustained care, and rehabilitation in managing poststroke patients. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Neurology News Network for the week ending January 21, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 19, 2024.

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesys Hospital explored the various interventions for managing spasticity after stroke, from stretching exercises to surgical procedures. [WATCH TIME: 3 minutes]

Aruna Bio's investigational treatment, AB126, is now set for a phase 1b/2a clinical trial targeting acute ischemic stroke, anticipated to begin in the first half of 2024.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Good functional outcome at 90 days was more prevalent among patients on argatroban plus antiplatelet therapy vs antiplatelet alone.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.

The medical director of the Inpatient Rehabilitation Unit at Ascension Genesis Hospital talked about the management of poststroke spasticity and highlighted the importance of awareness, education, and early intervention. [WATCH TIME: 5 minutes]

In addition to showing no significant dose-response relationship with ischemic stroke risk, milvexian was also associated with an increase in major bleeding events.

Catch up on any of the neurology news headlines you may have missed over the course of January 2024, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 5, 2024.

The director of neurocritical care and emergency neurology services at Westchester Medical Center Health System talked about a recently published paper that highlighted the need to address the disparity in quality metrics for stroke care, especially for intracerebral hemorrhage. [WATCH TIME: 4 minutes]

An international consortium of clinicians recommended evidence-based guidelines for intracerebral hemorrhage, in which early intervention, bundled care, and time-based metrics substantially improve neurological outcomes.

Over a year period on the combination agent, patients showed significantly amplified Aß42 and Aß40 levels with no significant differences in other biomarkers of ptau, GFAP, or neurofilament light.